Physician profile
Ilya Bilik
NPI 1093731374
$9,835.13
in general payments reported to CMS, 2019-2025
48 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,011 · 2020: $876 · 2021: $2,159 · 2022: $1,946 · 2023: $736 · 2024: $1,075 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,996.46 | 2019-2025 | Linzess, Viberzi, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,103.10 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $692.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $585.98 | 2021-2025 | |
| Glaxosmithkline, LLC. | $535.17 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $498.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $421.22 | 2019-2023 | |
| Pfizer INC. | $348.00 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $342.91 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $314.57 | 2019-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.49 | 2019-2023 | Trulance, Xifaxan |
| Lilly USA, LLC | $284.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $259.14 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $222.70 | 2021-2024 | Verquvo, Lagevrio, Januvia |
| Genzyme Corporation | $205.25 | 2023-2024 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Bilik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.